Derek R. Duckett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Derek R. Duckett has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrii Monastyrskyi
Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
1 shared publication - Isabel Adrados
Mechanisms of Growth Control and Cancer Lab, Instituto de Neurociencias, CSIC-UMH, Avda. Ramón y Cajal s/n, 03550 Sant Joan d’Alacant, Alicante, Spain
1 shared publication James M. Alburger
Department of Chemistry and †Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida 33458, United States
1 shared publicationJun Yong Choi
Department of Chemistry and †Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida 33458, United States
1 shared publication- Solomon Tadesse
Department of Biomedical and Pharmaceutical Sciences, L. S. Skaggs College of Pharmacy, Kasiska Division of Health Sciences, Idaho State University, Pocatello, ID, 83209, USA
1 shared publication Spencer D. Wood
Department of Chemistry and †Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida 33458, United States
1 shared publication
Latest Publications
- 9 December 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 13 (2) , 117-141
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, ...
- 9 December 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 13 (2) , 117-141
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, ...
- Open Access
- 22 November 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (12) , 1258-1263
In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors
We present the outcome of an in silico high throughput screen (HTS) and optimization of a small molecule Unc-51-Like Kinase 1 (ULK1) inhibitor hit, SR-17398, with an indazole core. Docking studies guided design efforts that led to inhibitors with increased activity vs ULK1 (IC50 < 50 nM). The most advanced molecules in this inhibitor series (3a and 3g) hold promise for further development into selective ULK1 molecular probes to interrogate the biology of ULK1 and to assess whether selectively targeting autophagy is an effective anticancer strategy.
- 22 November 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (12) , 1258-1263
Open AccessIn Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors
We present the outcome of an in silico high throughput screen (HTS) and optimization of a small molecule Unc-51-Like Kinase 1 (ULK1) inhibitor hit, SR-17398, with an indazole core. Docking studies guided design efforts that led to inhibitors with increased activity vs ULK1 (IC50 < 50 nM). The most advanced molecules in this inhibitor series (3a and 3g) hold promise for further development into selective ULK1 molecular probes to interrogate the biology of ULK1 and to assess whether selectively targeting autophagy is an effective anticancer strategy.